Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs
- 18 November 2008
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 105 (46), 18041-18046
- https://doi.org/10.1073/pnas.0806669105
Abstract
Until recently, all known antipsychotic drugs were thought to block the dopamine D2 receptor. New evidence that agonists of the metabotropic glutamate 2/3 (mGlu2/3) receptors ameliorate psychotic and affective symptoms of schizophrenia suggests that compounds with different molecular targets may act on a common cellular target to treat schizophrenia. We hypothesized that normalizing the activity of neurons in the orbitofrontal cortex (OFC), a region that is increasingly implicated in the pathophysiology of schizophrenia, presents such a target. We disrupted OFC activity in behaving rats with a use-dependent NMDA antagonist to model the NMDA hypofunction state that may occur in schizophrenia. This systemic treatment increased the activity of most pyramidal cells while inhibiting the activity of putative inhibitory GABA interneurons and increasing behavioral stereotypy. A similar pattern of OFC firing disruption was observed after amphetamine, which models a dopamine hyperactivity state in schizophrenia and which produces a pattern of firing disruption different from those of NMDA antagonists in other prefrontal cortex regions. Antipsychotic drugs haloperidol and clozapine, which target monoamine receptors, as well as an mGlu2/3 agonist and an mGlu5 receptor modulator proposed to have antipsychotic efficacy, reversed the impact of NMDA hypofunction on OFC cells and on behavior. A similar pattern of normalization of OFC activity was observed when treatments were given after amphetamine. Thus, proven or putative antipsychotic drugs with different mechanisms of action similarly reduced the impact of NMDA hypofunction and dopamine hyperfunction on OFC neurons, suggesting that these neurons are a candidate target for the therapeutic effects of antipsychotic medications.This publication has 50 references indexed in Scilit:
- DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophreniaBiological Psychology, 2008
- Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaTrends in Neurosciences, 2008
- Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal CortexBiological Psychiatry, 2007
- Selective Reinforcement Learning Deficits in Schizophrenia Support Predictions from Computational Models of Striatal-Cortical DysfunctionBiological Psychiatry, 2007
- Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humansProceedings of the National Academy of Sciences of the United States of America, 2007
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- Probabilistic reversal learning impairments in schizophrenia: Further evidence of orbitofrontal dysfunctionSchizophrenia Research, 2007
- Iowa Gambling Task in schizophrenia: A review and new data in patients with schizophrenia and co-occurring cannabis use disordersSchizophrenia Research, 2007
- Fine-Tuning of Awake Prefrontal Cortex Neurons by Clozapine: Comparison With Haloperidol and N-DesmethylclozapineBiological Psychiatry, 2007
- Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergenceMolecular Psychiatry, 2004